Literature DB >> 8956324

Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.

G M Pauletti1, S Gangwar, F W Okumu, T J Siahaan, V J Stella, R T Borchardt.   

Abstract

PURPOSE: To evaluate a cyclic acyloxyalkoxycarbamate prodrug of a model hexapeptide (H-Trp-Ala-Gly-Gly-Asp-Ala-OH) as a novel approach to enhance the membrane permeation of the peptide and stabilize it to metabolism.
METHODS: Conversion to the linear hexapeptide was studied at 37 degrees C in aqueous buffered solutions and in various biological milieus having measurable esterase activities. Transport and metabolism characteristics were assessed using the Caco-2 cell culture model.
RESULTS: In buffered solutions the cyclic prodrug degraded chemically to the linear hexapeptide in stoichiometric amounts. Maximum stability was observed between pH 3-4. In 90% human plasma (t1/2 = 100 +/- 4 min) and in homogenates of the rat intestinal mucosa (t1/2 = 136 +/- 4 min) and rat liver (t1/2 = 65 +/- 3 min), the cyclic prodrug disappeared faster than in buffered solution, pH 7.4 (t1/2 = 206 +/- 11 min). Pretreatment of these media with paraoxon significantly decreased the degradation rate of the prodrug. When applied to the apical side of Caco-2 cell monolayers, the cyclic prodrug (t1/2 = 282 +/- 25 min) was significantly more stable than the hexapeptide (t1/2 = 14 min) and at least 76-fold more able to permeate (Papp = 1.30 +/- 0.15 x 10(-7) cm/s) than the parent peptide (Papp < or = 0.17 x 10(-8) cm/s).
CONCLUSIONS: Preparation of a cyclic peptide using an acyloxyalkoxy promoiety reduced the lability of the peptide to peptidase metabolism and substantially increased its permeation through biological membranes. In various biological media the parent peptide was released from the prodrug by an apparent esterase-catalyzed reaction, sensitive to paraoxon inhibition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956324     DOI: 10.1023/a:1016472119387

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

Review 2.  Prodrugs of peptides and proteins for improved formulation and delivery.

Authors:  R Oliyai; V J Stella
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

Review 3.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs.

Authors:  M Inoue; M Morikawa; M Tsuboi; M Sugiura
Journal:  Jpn J Pharmacol       Date:  1979-02

5.  Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

6.  Delta-sleep-inducing peptide: solution conformational studies of a membrane-permeable peptide.

Authors:  R A Gray; D G Vander Velde; C J Burke; M C Manning; C R Middaugh; R T Borchardt
Journal:  Biochemistry       Date:  1994-02-15       Impact factor: 3.162

7.  Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers.

Authors:  P F Augustijns; R T Borchardt
Journal:  Drug Metab Dispos       Date:  1995-12       Impact factor: 3.922

8.  Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues.

Authors:  K Takahashi; S Tamagawa; H Sakano; T Katagi; N Mizuno
Journal:  Biol Pharm Bull       Date:  1995-10       Impact factor: 2.233

9.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

10.  Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.

Authors:  C S Cook; P J Karabatsos; G L Schoenhard; A Karim
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

View more
  15 in total

1.  Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.

Authors:  M Sudoh; G M Pauletti; W Yao; W Moser; A Yokoyama; A Pasternak; P A Sprengeler; A B Smith; R Hirschmann; R T Borchardt
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

2.  Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide.

Authors:  G M Pauletti; S Gangwar; B Wang; R T Borchardt
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

3.  Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.

Authors:  E V Batrakova; S Li; D W Miller; A V Kabanov
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

4.  Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell monolayers.

Authors:  F W Okumu; G M Pauletti; D G Vander Velde; T J Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

5.  A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.

Authors:  G P Camenisch; W Wang; B Wang; R T Borchardt
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

6.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.

Authors:  O S Gudmundsson; G M Pauletti; W Wang; D Shan; H Zhang; B Wang; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

9.  Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.

Authors:  O S Gudmundsson; K Nimkar; S Gangwar; T Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

10.  Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.

Authors:  A Bak; O S Gudmundsson; G J Friis; T J Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.